@entity272 , such as @entity483 , can cause considerable impairment of life quality. Their treatment is mainly driven by systemic or topical glucocorticosteroids which have the risk of many side effects. Recently, immunosuppressive macrolides which act via the inhibition of cytokine expression in T-lymphocytes have been shown to exert good therapeutic potency in @entity272 . @entity205 , widely used in transplantation medicine, is also effective in @entity1569 and @entity483 but is not suitable for topical treatment. @entity1140 ( @entity1140 ) has been found to be 10-100 times more potent than @entity205 and to penetrate skin much better due to a lower molecular weight. Initial clinical investigations have shown efficacy of topical @entity1140 in @entity1 with @entity483 . Large multi-centre studies have proven that long-term therapy with 0.03% and 0.1% @entity1140 ointment reveals effectiveness and safety both in adults and in @entity1 with severe @entity483 . A burning sensation at the site of application is the most frequently observed local side effect. Relevant systemic adverse events were not detected. In Japan and the US, the drug is already licensed for the treatment of @entity483 . The European admission for the pharmaceutical market is expected in the year 2002. @entity1140 represents a milestone in topical therapy of @entity272 which has so far been dominated by corticosteroid formulations and gives hope for the development of further topical immunosuppressive agents of its class in the future.

Topical XXXX for the treatment of inflammatory @entity272 .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity483 :: ('MESH:D003876', 'Disease') :: ['atopic eczema'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity272 :: ('MESH:D012871', 'Disease') :: ['inflammatory skin disorders', 'Chronic inflammatory skin disorders'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['Cyclosporin', 'cyclosporin'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['FK506', 'Tacrolimus', 'tacrolimus']
@entity1140 :: (MESH:D016559,Chemical) :: ['tacrolimus']
